Medscape Medical News > FDA Approvals Doug Brunk June 25, 2024 The Food and Drug Administration has approved a topical anticholinergic, sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis in adults and children aged ≥ 9 years. According to a press release from Botanix Pharmaceuticals, which developed the product and will market...
Category: <span>Clinical Practice</span>
Post
Already 30 minutes of exercise increases the proportion of tumor-killing white blood cells in blood
NEWS RELEASE 3-JUL-2024 Peer-Reviewed PublicationUNIVERSITY OF TURKU A new Finnish study from University of Turku shows that already a 30-minute exercise can increase the proportion of tumor-killing white blood cells in the bloodstream of breast cancer patients. White blood cells, the cells of our immune system, fight against cancer, bacteria, and viruses. However, not all...
Post
Weight loss surgery cuts risk of heart complications and death in patients with obstructive sleep apnea and obesity
by Cleveland Clinic Credit: Unsplash/CC0 Public Domain A Cleveland Clinic study shows that bariatric surgery performed in patients with obesity and moderate to severe obstructive sleep apnea is associated with a significantly lower risk of death and major adverse cardiovascular events, compared with patients who did not have the surgery. This study was published in...
Post
Do Artificial Sweeteners Really Help People With Diabetes?
It seems intuitive that because people with type 2 diabetes (T2D) generally need to avoid sugar, clinicians should recommend eating foods and using recipes containing artificial sweeteners such as sucralose instead. Splenda, which produces sucralose and other non-sugar sweeteners (NSS), is a sponsor of the American Diabetes Association (ADA) Diabetes Food Hub. Earlier this year,...
Post
Approaching the sarcopenic patient with nonalcoholic steatohepatitis-related cirrhosis
by Xia & He Publishing Inc. Credit: Journal of Clinical and Translational Hepatology (2024). DOI: 10.14218/JCTH.2023.00207 Nonalcoholic fatty liver disease (NAFLD), now reclassified as metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe form, nonalcoholic steatohepatitis (NASH), renamed metabolic dysfunction-associated steatohepatitis (MASH), are increasingly recognized as major contributors to chronic liver disease (CLD) and...
Post
FDA approves Capvaxive pneumococcal 21-valent conjugate vaccine
by Lori Solomon The U.S. Food and Drug Administration has approved Merck’s Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Capvaxive is specifically designed to help protect adults against the serotypes that cause the majority of invasive pneumococcal disease cases, including Streptococcus pneumoniae serotypes 3, 6A,...
Post
FDA expands pediatric indication for Rinvoq
by Lori Solomon The U.S. Food and Drug Administration has expanded indications for AbbVie’s Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). Rinvoq is indicated for pediatric patients with an inadequate response or intolerance to one or more tumor necrosis factor...
Post
Enhancing Medical Billing Through Advanced Data Analytics
Medical billing is a critical factor in the medical industry and involves submitting and following up on claims. These follow-ups are conducted with health insurance companies so medical practitioners can be reimbursed timeously for their services. In theory, this is a simple process. However, it remains complex as there are multiple considerations, like coding accuracy,...
Post
New Guidance on CGRPs as First-Line Migraine Prevention: How/Will it Change Clinical Practice?
Eve Bender June 20, 2024 A position statement released by the American Headache Society (AHS) earlier this year recommended adding calcitonin gene-related peptide (CGRP)–targeting medications to the list of first-line therapies for migraine prevention. The guidance replaces recommendations published in 2021 that advised clinicians consider CGRP therapy only after patients fail at least two classes...
Post
Ghrelin Paradox: Unlocking New Avenues in Obesity Management
Ghrelin Paradox: Unlocking New Avenues in Obesity ManagementDimpi Desai, MD; Ashni Dharia, MD DISCLOSURES | June 21, 2024 Despite their best efforts, 80% of people who lose weight regain itand many end up heavier within 5 years. Why? Our bodies fight back, revving up hunger while slowing metabolism after weight loss. In ongoing obesity discussions,...